Drugs / NEBENTAN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00050297 | ? → Feb 2004 | prostate cancer | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00048659 | ? → Jun 2004 | hormone-resistant prostate carcinoma | Astellas Pharma Inc | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEBENTAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107760 ↗ |
| Known as | HE-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107760 ↗ |
| Known as | Nebentan potassium | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107760 ↗ |
| Known as | YM598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00050297 ↗ |
| Action | Inhibit | “Endothelin receptor ET-A antagonist” CHEMBL2107760 ↗ |
| Modality | Small molecule | — CHEMBL2107760 ↗ |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL2107760 ↗ |